RHYTHM PHARMACEUTICALS INC (RYTM) Forecast, Price Target & Analyst Ratings
NASDAQ:RYTM • US76243J1051
89.43 USD
-0.13 (-0.15%)
Last: Mar 4, 2026, 11:55 AM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for RHYTHM PHARMACEUTICALS INC (RYTM).
Forecast Snapshot
Consensus Price Target
$142.61
+ 59.46% Upside
Next Earnings Forecast
Release DateMay 5, 2026
PeriodQ1 / 2026
EPS Estimate-$0.85
Revenue Estimate57.871M
ChartMill Buy Consensus
85.45%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$142.61
Upside
+ 59.46%
From current price of $89.43 to mean target of $142.61, Based on 22 analyst forecasts
Low
$111.10
Median
$144.33
High
$175.35
Price Target Revisions
1 Month
1.12%
3 Months
11.72%
Price Target Summary
22 analysts have analysed RYTM and the average price target is 142.61 USD. This implies a price increase of 59.46% is expected in the next year compared to the current price of 89.43.
The average price target has been revised upward by 11.72% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
85.45%
RYTM was analyzed by 22 analysts. The buy percentage consensus is at 85. So analysts seem to be very confident about RYTM.
In the previous month the buy percentage consensus was at a similar level.
RYTM was analyzed by 22 analysts, which is quite many. So the average rating should be quite meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-02 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2026-03-02 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2026-02-27 | Citizens | Maintains | Market Outperform -> Market Outperform |
| 2026-02-27 | Guggenheim | Maintains | Buy -> Buy |
| 2026-02-27 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2026-02-26 | Needham | Maintains | Buy -> Buy |
| 2026-02-19 | RBC Capital | Initiate | Outperform |
| 2026-01-20 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2026-01-20 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2026-01-09 | Needham | Maintains | Buy -> Buy |
| 2025-12-22 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-12-17 | Guggenheim | Maintains | Buy -> Buy |
| 2025-12-12 | Citizens | Maintains | Market Outperform -> Market Outperform |
| 2025-12-12 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-12-12 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-12-11 | Needham | Maintains | Buy -> Buy |
| 2025-11-25 | Citigroup | Initiate | Buy |
| 2025-11-10 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-11-07 | Needham | Maintains | Buy -> Buy |
| 2025-11-04 | Needham | Maintains | Buy -> Buy |
| 2025-10-17 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-10-16 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-09-29 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-09-25 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2025-09-25 | Morgan Stanley | Maintains | Overweight -> Overweight |
Next Earnings Forecast Details
Next Earnings Details
Release DateMay 5, 2026
PeriodQ1 / 2026
EPS Estimate-$0.85
Revenue Estimate57.871M
Revenue Q2Q76.95%
EPS Q2Q-4.63%
Number of Analysts17
Next Earnings Revisions
Revenue (1 Month)
0.12%
Revenue (3 Months)
1.72%
EPS (1 Month)
0.58%
EPS (3 Months)
-2.00%
Next Earnings Summary
RYTM is expected to report earnings on 5/5/2026. The consensus EPS estimate for the next earnings is -0.85 USD and the consensus revenue estimate is 57.87M USD.
The next earnings revenue estimate has been revised upward by 1.72% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 77.428M 227.53% | 130.126M 68.06% | 189.757M 45.83% | 298.79M 57.46% | 554.56M 85.60% | 951.6M 71.60% | 1.483B 55.84% | 2.096B 41.34% | 2.42B 15.46% | 2.835B 17.15% | 3.345B 17.99% | |
| EBITDA YoY % growth | -182.599M -2.88% | -263.94M -44.55% | -190.678M 27.76% | -166.648M 12.60% | 11.211M 106.73% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -184.357M -2.90% | -265.503M -44.02% | -192.016M 27.68% | -174.166M 9.30% | 26.859M 115.42% | 430.59M 1,503.15% | 791.02M 83.71% | 1.335B 68.77% | 1.605B 20.22% | 1.945B 21.18% | 2.382B 22.47% | |
| Operating Margin | -238.10% | -204.04% | -101.19% | -58.29% | 4.84% | 45.25% | 53.34% | 63.69% | 66.32% | 68.61% | 71.21% | |
| EPS YoY % growth | -3.20 8.05% | -4.49 -40.31% | -3.11 30.73% | -3.08 0.84% | -0.44 85.64% | 4.24 1,057.69% | 8.25 94.43% | 12.65 53.38% | 16.60 31.19% | 19.01 14.55% | 22.89 20.41% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.85 -4.63% | -0.79 -5.32% | -0.66 19.04% | -0.61 16.54% | 0.18 121.66% | 0.34 142.61% | 0.67 201.41% | 0.87 242.31% |
| Revenue Q2Q % growth | 57.871M 76.95% | 69.267M 42.81% | 80.083M 56.11% | 90.041M 57.27% | 107.1M 85.07% | 122.4M 76.71% | 135.66M 69.40% | 151.98M 68.79% |
| EBITDA Q2Q % growth | -57.903M -24.20% | -51.602M -15.87% | -37.61M 27.09% | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -54.905M -16.81% | -51.304M -13.26% | -43.372M 17.63% | -39.678M 15.69% | N/A | N/A | N/A | N/A |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
49.84%
EPS Next 5 Year
43.42%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
70.65%
Revenue Next 5 Year
61.38%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
RHYTHM PHARMACEUTICALS INC / RYTM Forecast FAQ
Can you provide the average price target for RHYTHM PHARMACEUTICALS INC stock?
22 analysts have analysed RYTM and the average price target is 142.61 USD. This implies a price increase of 59.46% is expected in the next year compared to the current price of 89.43.
When does RHYTHM PHARMACEUTICALS INC (RYTM) report earnings?
RHYTHM PHARMACEUTICALS INC (RYTM) will report earnings on 2026-05-05.
What are the consensus estimates for RHYTHM PHARMACEUTICALS INC (RYTM) next earnings?
The consensus EPS estimate for the next earnings of RHYTHM PHARMACEUTICALS INC (RYTM) is -0.85 USD and the consensus revenue estimate is 57.87M USD.
What is the consensus rating for RYTM stock?
The consensus rating for RHYTHM PHARMACEUTICALS INC (RYTM) is 85.4545 / 100 . This indicates that analysts generally have a positive outlook on the stock.